
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group is a leader in the regenerative biomaterial industry, with a strong track record and established relationships in the wound care and surgical markets. The company also has a best-in-class suite of clinical data to support the effectiveness and economic benefits of its amniotic tissue products. While the recent Medicare reimbursement changes have negatively impacted the company's sales, we believe that MiMedx is well-positioned to outperform in the new environment thanks to its vertically integrated manufacturing infrastructure and established sales force. Additionally, the company's recent restructuring and cost reduction initiative is expected to result in significant operating expense savings, further improving its financial outlook.
Bears say
MiMedx Group is facing challenges with reimbursement and declining sales in its key Wound Care segment due to changes in the CMS reimbursement policies. While management has implemented cost reduction initiatives and foresees a slow recovery, this disruption is expected to continue to have a negative impact on the company's top-line growth. Risks related to donorship, competition, and contracts with GPOs and IDNs also pose potential threats to the company's future business.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares